Therapixel Announces Closing of €15M Series B Funding to Deploy MammoScreen® 2D/3D
The Company will accelerate the commercial deployment of its Artificial Intelligence reading solution for 2D/3D mammography, with a focus on the United States
PARIS, NICE, France and CHICAGO, May 12, 2022 /PRNewswire/ — Therapixeldesigner and supplier of MammoScreen® an Artificial Intelligence software to assist with reading for mammography, announces today a fundraising of 15 M€ in series B.
This operation was led by Crédit Mutuel Innovation and CapHorn, joined by Verve, Sham Innovation Santé and historical investors Omnes, IT-Translation, M-Capital and Région Sud Investissement. This fundraising will allow Therapixel to accelerate its commercial presence in the United States, launch more unique features for MammoScreen and push the boundaries of its intelligent reading aid for mammography even further.
With two regulatory clearances from the FDA in the United States for 2D and 3D mammography (tomosynthesis), MammoScreen is already being deployed in large networks of breast cancer screening clinics. MammoScreen uses a unique score, MammoScreen Score™ to report at a glance the level of suspicion of a mammogram. This makes it possible to confirm lesions that are certain and to save valuable time with a faster reading of benign cases. Radiologists can thus feel more confident in their decision and spend more time on difficult cases that require more attention.
Matthieu Leclerc-Chalvet, CEO of Therapixel States: “We are very pleased to close this new funding round with investors active in digital health. These funds will allow us to expand our US team with new sales and support people and accelerate our commercial activities. With an already strong pipeline base, Therapixel is poised for significant growth and will have a decisive impact on breast cancer screening.”
Pierre Fillard, Scientific and Technological Director and Founder of Therapixel keep on going: “This is a major milestone for Therapixel and I am proud of the achievements of our teams in collaboration with partner radiologists. We will accelerate the launch of a new generation of AI that will allow women to benefit from detection more early with less anxiety and assist radiologists in the ever-increasing demand for imaging.We will also advance regulatory and clinical developments that will solidify our leadership position as the AI solution of choice for radiologists reading the mammography”
Jérôme Féraud, Director of Health Investments and Tanguy Besson, Partner at Crédit Mutuel Innovation, Continue :
“Beyond the technological performance of the solutions developed by Therapixel, it seemed obvious to us to support the deployment of MammoScreen, which improves the detection of breast cancer, at a time when women are in a particularly stressful situation. . The overall ergonomics of the solution provide radiologists with a valuable image analysis tool that allows them to optimize their time and focus their expertise on the specifics of the case.”
François Santi, Principal at CapHorn keep on going :
“We are very pleased to support Therapixel in this new strategic investment round, together with several experienced investors in the field of digital health. We have followed Therapixel for several months and have been impressed by the execution capacity of the team and their achievements over the course of We are very pleased to support Therapixel’s commercial expansion in the United States and help the company set a new standard in breast cancer detection.
With this new funding round, Therapixel has raised more than €20 million since its creation in 2013.
The following Council and Advisor assisted in this round:
Legal counsel: JonesDay – Renaud Bonnet
Financial Advisors: Fraser Finance – Olivier Koechlin and Deborah Herst
Neliya Tumbeva (Therapixel) – [email protected]
Louisa Mesnard (computer translation) – [email protected]
Véronique Richez-Lerouge (Crédit Mutuel Innovation) – [email protected]
Aurélie Blanchard-Massoni (Omnes Capital) [email protected]
Valérie Roché-Melin (South Investment Region) – [email protected]
Therapixel is a French company specializing in the design and marketing of medical imaging software based on AI, with the aim of providing relevant information at the right time to healthcare professionals. Winner of DREAM Challenge digital mammography in 2017, the global AI breast cancer detection competition, Therapixel developed MammoScreen®, software to help interpret 2D and 3D screening mammograms. With MammoScreen, even experienced radiologists can improve their performance, feel more confident in their judgment and reassure women faster. Learn more about mammoscreen.com
CapHorn is a Paris-based venture capital firm that invests in innovative companies across Europe, focusing on health technologies, sustainability and enterprise software. We partner with exceptional entrepreneurs and commit investments of 1 to 15 million euros in high growth companies, from early stage to late stage. CapHorn has an active portfolio of 50 companies and supports their development by relying on its vast network of business leaders. The firm, created in 2011, is part of the Anaxago group.
CAPHOR: TRUST, FUNDING, NETWORK. Learn more about: caphorn.vc
Credit Mutuel Innovation is the subsidiary of Crédit Mutuel Equity (€3.5 billion in managed capital) specializing in venture capital investments. Crédit Mutuel Innovation invests its equity in tickets from €1 to €20 million, in innovative digital, life sciences and deeptech companies.
Crédit Mutuel Innovation enables entrepreneurs to develop their growth potential by putting them in contact with other companies in their ecosystem. Because it takes more than 5 years to create a world leader, Crédit Mutuel Innovation invests its own funds over the long term and builds lasting relationships with the entrepreneurs it supports. www.creditmutuel-equity.eu
Omnes is a leading private equity and infrastructure investor. With more than €5 billion in assets under management, it provides companies with the capital they need to finance their growth, in three key areas: venture capital, development and transmission capital and infrastructure. Omnes is 100% owned by its employees. She is committed to ESG factors and created the Omnes Foundation to finance initiatives in favor of children and young people. It is a signatory to the Principles for Responsible Investment (PRI) of the United Nations. www.omnescapital.com
Computer translation is now part of Elaia. Elaia is a leading European venture capital firm with a strong technological DNA. We support technology disruptors with global ambition, from early stage to growth development. For the past 20 years, our commitment has been to deliver high performance with values. We’re proud to have been an active partner in over 100 startups, including success stories like Criteo (Nasdaq), Orchestra Networks (acquired by Tibco), Volterra (acquired by F5), Mirakl (valued at $3.5 billion Series E) and Shift Technology (valued at over $1 billion in Series D). Learn more http://www.elaia.com • @Elaia_Partners
M/Capital Partners is a French asset management company that mobilizes mixed, private and state financing to invest in businesses and real estate to foster the creation of new growing, resilient and inclusive values. M/Capital believes that entrepreneurs are in a unique position to transform the world in which we live. Therefore, M/Capital supports the men and women who work to empower people, foster cohesion and preserve our planet. M/Capital Group has more than 800 million euros under management across four divisions (Real Estate, Venture Capital, Private Equity and Private Debt) and relies on 65 talents based in Paris, Toulouse, Marseille, Montpellier and Nice (France ). www.mcapital.fr
South Region Investment is the regional investment company created in 2010 by the South Region to support the emergence and development of growth companies. Région Sud Investissement, with a capital of €146 million, receives 42% of its capacity from the European Union via the FEDER fund. It has invested in 335 companies so far and plans to launch a new equity fund called “RSI React Eu” for growing companies that have been affected by the health crisis. www.regionsudinvestment.com
Show original content to download multimedia:https://www.prnewswire.com/news-releases/therapixel-announces-close-of-15-m-series-b-financing-to-deploy-mammoscreen-2d3d-301545512.html